The pharmacokinetic evaluation of artemisinin drugs for the treatment of malaria in paediatric populations

Expert Opinion on Drug Metabolism and Toxicology

Volumn 7, Issue 4, 2011, Pages 427-439

  Mercer, Amy E ^a   Sarr Sallah, Mariama ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

artemisinin; malaria; malnutrition; metabolism; paediatric; pharmacokinetic

Indexed keywords

ARTEETHER; ARTEMETHER; ARTEMISININ; ARTESUNATE; DIHYDROARTEMISININ;

AREA UNDER THE CURVE; CHILD CARE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; ENVIRONMENTAL FACTOR; HUMAN; MALARIA; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; NUTRITION; POPULATION RESEARCH; PUBLICATION; REVIEW; TIME TO MAXIMUM PLASMA CONCENTRATION;

ANTIMALARIALS; ARTEMISININS; CHILD; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE; EVALUATION STUDIES AS TOPIC; HUMANS; MALARIA; PEDIATRICS; PROTEIN-ENERGY MALNUTRITION;

EID: 79952957021     PISSN: 17425255     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425255.2011.557064     Document Type: Review

References (76)

1. Carter R, Mendis KN. Evolutionary and historical aspects of the burden of malaria. Clin Microbiol Rev 2002;15:564-94 (Pubitemid 41184079)
2. WHO. Malaria report, 2008. Available from: http://wwwwhoint/malaria/ publications/atoz/9789241563697/en/indexhtml 2008
3. Nosten F, White NJ. Artemisinin-based combination treatment of falciparum malaria. Am J Trop Med Hyg 2007;77:181-92
4. Park BK, O?Neill PM, Maggs JL, et al. Safety assessment of peroxide antimalarials: clinical and chemical perspectives. Br J Clin Pharmacol 1998;46:521-9 (Pubitemid 28522114)
5. WHO. Antimalarial Drug Combination Therapy. Report of a WHO Technical Consultation. WHO/CDS/RBM/200135 2001
6. Mwesigwa J, Parikh S, McGee B, et al. Pharmacokinetics of artemether-lumefantrine and artesunate-amodiaquine in children in Kampala, Uganda. Antimicrob Agents Chemother 2010;54:52-9
7. Stepniewska K, Taylor W, Sirima SB, et al. Population pharmacokinetics of artesunate and amodiaquine in African children. Malar J 2009;8:200
8. Abdulla S, Sagara I, Borrmann S, et al. Efficacy and safety of artemether-lumefantrine dispersible tablets compared with crushed commercial tablets in African infants and children with uncomplicated malaria: a randomised, single-blind, multicentre trial. Lancet 2008;372:1819-27
9. Kurth F, Belard S, Adegnika AA, et al. Do paediatric drug formulations of artemisinin combination therapies improve the treatment of children with malaria? A systematic review and meta-analysis. Lancet Infect Dis 2010;10:125-32
10. Faye B, Ndiaye JL, Tine R, et al. A randomized trial of artesunate mefloquine versus artemether lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Senegalese children. Am J Trop Med Hyg 2010;82:140-4
11. Bouyou-Akotet MK, Ramharter M, Ngoungou EB, et al. Efficacy and safety of a new pediatric artesunate-mefloquine drug formulation for the treatment of uncomplicated falciparum malaria in Gabon. Wien Klin Wochenschr 2010;122:173-8
12. O?Neill PM, Posner GH. A medicinal chemistry perspective on artemisinin and related endoperoxides. J Med Chem 2004;47:2945-64 (Pubitemid 38702690)
13. Meshnick SR, Yang YZ, Lima V, et al. Iron-dependent free radical generation from the antimalarial agent artemisinin (qinghaosu). Antimicrob Agents Chemother 1993;37:1108-14 (Pubitemid 23141328)
14. Stocks PA, Bray PG, Barton VE, et al. Evidence for a common non-heme chelatable-iron-dependent activation mechanism for semisynthetic and synthetic endoperoxide antimalarial drugs. Angew ChemInt Ed 2007;46:6278-83 (Pubitemid 47329416)
15. Eckstein-Ludwig U, Webb RJ, van Goethem IDA, et al. Artemisinins target the SERCA of plasmodium falciparum. Nature 2003;424:957-61 (Pubitemid 37051688)
16. Berman PA, Adams PA. Artemisinin enhances heme-catalysed oxidation of lipid membranes. Free Radic Biol Med 1997;22:1283-8 (Pubitemid 27171971)
17. Robert A, Benoit-Vical F, Claparols C, et al. The antimalarial drug artemisinin alkylates heme in infected mice. Proc Natl Acad Sci USA 2005;102:13676-80 (Pubitemid 41420907)
18. Li XQ, Bjorkman A, Andersson TB, et al. Identification of human cytochrome P(450)s that metabolise anti-parasitic drugs and predictions of in vivo drug hepatic clearance from in vitro data. Eur J Clin Pharmacol 2003;59:429-42 (Pubitemid 37214951)
19. Maggs JL, Bishop LPD, Edwards G, et al. Biliary metabolites of beta-artemether in rats: Biotransformations of an antimalarial endoperoxide. Drug Metab Dispos 2000;28:209-17 (Pubitemid 30069006)
20. Maggs JL, Madden S, Bishop LP, et al. The rat biliary metabolites of dihydroartemisinin, an antimalarial endoperoxide. Drug Metab Dispos 1997;25:1200-4 (Pubitemid 27446591)
21. Nagar S, Remmel RP. Uridine diphosphoglucuronosyltransferase pharmacogenetics and cancer. Oncogene 2006;25:1659-72
22. Kerb R, Fux R, Morike K, et al. Pharmacogenetics of antimalarial drugs: effect on metabolism and transport. Lancet Infect Dis 2009;9:760-74
23. Navaratnam V, Mansor SM, Sit NW, et al. Pharmacokinetics of artemisinin-type compounds. Clin Pharmacokinet 2000;39:255-70
24. Medhi B, Patyar S, Rao RS, et al. Pharmacokinetic and toxicological profile of artemisinin compounds: an update. Pharmacology 2009;84:323-32
25. Clark RL. Embryotoxicity of the artemisinin antimalarials and potential consequences for use in women in the first trimester. Reprod Toxicol 2009;28:285-96
26. Mercer AE, Maggs JL, Sun XM, et al. Evidence for the involvement of carbon-centered radicals in the induction of apoptotic cell death by artemisinin compounds. J Biol Chem 2007;282:9372-82 (Pubitemid 47104599)
27. Mercer AE. The role of bioactivation in the pharmacology and toxicology of the artemisinin-based antimalarials. Curr Opin Drug Discov Dev 2009;12:125-32
28. Disbrow GL, Baege AC, Kierpiec KA, et al. Dihydroartemisinin is cytotoxic to papillomavirus-expressing epithelial cells in vitro and in vivo. Cancer Res 2005;65:10854-61 (Pubitemid 41713353)
29. Zhang S, Gerhard GS. Heme mediates cytotoxicity from artemisinin and serves as a general anti-proliferation target. Plos One 2009;4:e7472
30. Li QG, Lugt CB, Looareesuwan S, et al. Pharmacokinetic investigation on the therapeutic potential of artemotil (beta-arteether) in Thai patients with severe plasmodium falciparum malaria. Am J Trop Med Hyg 2004;71:723-31 (Pubitemid 40075620)
31. Looareesuwan S, Oosterhuis B, Schilizzi BM, et al. Dose-finding and efficacy study for i.m. artemotil (beta-arteether) and comparison with i.m. artemether in acute uncomplicated P-falciparum malaria. Br J Clin Pharmacol 2002;53:492-500 (Pubitemid 34526501)
32. Keoluangkhot V, Green MD, Nyadong L, et al. Impaired clinical response in a patient with uncomplicated falciparum malaria who received poor-quality and underdosed intramuscular artemether. Am J Trop Med Hyg 2008;78:552-5 (Pubitemid 351845155)
33. Price RN, Cassar C, Brockman A, et al. The pfmdr1 gene is associated with a multidrug-resistant phenotype in plasmodium falciparum from the western border of Thailand. Antimicrob Agents Chemother 1999;43:2943-9
34. Angus BJ, Thaiaporn I, Chanthapadith K, et al. Oral artesunate dose-response relationship in acute falciparum malaria. Antimicrob Agents Chemother 2002;46:778-82 (Pubitemid 34157663)
35. Gordi T, Lepist EI. Artemisinin derivatives: toxic for laboratory animals, safe for humans? Toxicol Lett 2004;147:99-107 (Pubitemid 38130178)
36. Davis TME, Binh TQ, Ilett KF, et al. Penetration of dihydroartemisinin into cerebrospinal fluid after administration of intravenous artesunate in severe falciparum malaria. Antimicrob Agents Chemother 2003;47:368-70 (Pubitemid 36070387)
37. Batty KT, Thu LTA, Davis TME, et al. A pharmacokinetic and pharmacodynamic study of intravenous vs oral artesunate in uncomplicated falciparum malaria. Br J Clin Pharmacol 1998;45:123-9 (Pubitemid 28045678)
38. Batty KT, Thu LA, Ilett KF, et al. A pharmacokinetic and pharmacodynamic study of artesunate for vivax malaria. Am J Trop Med Hyg 1998;59:823-7 (Pubitemid 28524545)
39. Karunajeewa HA, Ilett KF, Dufall K, et al. Disposition of artesunate and dihydroartemisinin after administration of artesunate suppositories in children from Papua New Guinea with uncomplicated malaria. Antimicrob Agents Chemother 2004;48:2966-72 (Pubitemid 38989162)
40. Halpaap B, Ndjave M, Paris M, et al. Plasma levels of artesunate and dihydroartemisinin in children with plasmodium falciparum malaria in Gabon after administration of 50-milligram artesunate suppositories. Am J Trop Med Hyg 1998;58:365-8 (Pubitemid 28160762)
41. Sirivichayakul C, Sabchareon A, Pengsaa K, et al. Comparative study of the effectiveness and pharmacokinetics of two rectal artesunate oral mefloquine combination regimens for the treatment of uncomplicated childhood falciparum malaria. Ann Trop Paediatr 2007;27:17-24 (Pubitemid 47628957)
42. Sabchareon A, Attanath P, Chanthavanich P, et al. Comparative clinical trial of artesunate suppositories and oral artesunate in combination with mefloquine ln the treatment of children with acute falciparum malaria. Am J Trop Med Hyg 1998;58:11-16 (Pubitemid 28071402)
43. Krishna S, Planche T, Agbenyega T, et al. Bioavailability and preliminary clinical efficacy of intrarectal artesunate in Ghanaian children with moderate malaria. Antimicrob Agents Chemother 2001;45:509-16 (Pubitemid 32105288)
44. WHO. FDA briefing document for the anti-infective drug products advisory committee: artesunate rectal capsules. World Health Organization Global Health Malaria Program; 2002. p. NDA21-242
45. Bethell DB, TejaIsavadharm P, Cao XTP, et al. Pharmacokinetics of oral artesunate in children with moderately severe plasmodium falciparum malaria. Trans R Soc Trop Med Hyg 1997;91:195-8 (Pubitemid 27197293)
46. Ramharter M, Kurth FM, Belard S, et al. Pharmacokinetics of two paediatric artesunate-mefloquine drug formulations in the treatment of uncomplicated falciparum malaria in Gabon. J Antimicrob Chemother 2007;60:1091-6 (Pubitemid 47617759)
47. Sidhu JS, Ashton M, Huong NV, et al. Artemisinin population pharmacokinetics in children and adults with uncomplicated falciparum malaria. Br J Clin Pharmacol 1998;45:347-54 (Pubitemid 28138826)
48. Ramharter M, Kurth F, Schreier AC, et al. Fixed-dose pyronaridine- artesunate combination for treatment of uncomplicated falciparum malaria in pediatric patients in Gabon. J Infect Dis 2008;198:911-19
49. Simpson JA, Agbenyega T, Barnes KI, et al. Population pharmacokinetics of artesunate and dihydroartemisinin following intra-rectal dosing of artesunate in malaria patients. PLoS Med 2006;3:e444
50. Yeung S, Socheat D, Moorthy VS, et al. Artemisinin resistance on the Thai-Cambodian border. Lancet 2009;374:1418-19
51. van den Anker JN. Developmental pharmacology. Dev Disabil Res Rev 2010;16:233-8
52. Mahmood I. Prediction of drug clearance in children: impact of allometric exponents, body weight, and age. Ther Drug Monit 2007;29:271-8 (Pubitemid 47262255)
53. Kearns GL, Abdel-Rahman SM, Alander SW, et al. Developmental pharmacology -drug disposition, action, and therapy in infants and children. N Engl J Med 2003;349:1157-67 (Pubitemid 37122329)
54. Tetelbaum M, Finkelstein Y, Nava-Ocampo AA, et al. Back to basics: understanding drugs in children: pharmacokinetic maturation. Pediatr Rev 2005;26:321-8
55. Sodemann M, Jakobsen M, Molbak K, et al. Malaria parasitemia and childhood diarrhea in a peri-urban area of Guinea-Bissau. Am J Trop Med Hyg 1999;61:336-8 (Pubitemid 29380272)
56. Johnson TN. The development of drug metabolising enzymes and their influence on the susceptibility to adverse drug reactions in children. Toxicology 2003;192:37-48 (Pubitemid 37153342)
57. Rakhmanina NY, van den Anker JN. Pharmacological research in pediatrics: from neonates to adolescents. Adv Drug Deliv Rev 2006;58:4-14
58. Edgington AN, Willman W. Physiology-based versus allometric scaling of clearance in children; an eliminating process based comparison. Paediatr Perinat Drug Ther 2006;7:146-53
59. Benedetti MS, Baltes EL. Drug metabolism and disposition in children. Fundam Clin Pharmacol 2003;17:281-99 (Pubitemid 36774164)
60. de Wildt SN, Kearns GL, Leeder JS, et al. Glucuronidation in humans -Pharmacogenetic and developmental aspects. Clin Pharmacokinet 1999;36:439-52 (Pubitemid 29317491)
61. Schaible UE, Kaufmann SHE. Malnutrition and infection: complex mechanisms and global impacts. PLoS Med 2007;4:0806-12 (Pubitemid 46842571)
62. Oshikoya KA, Senbanjo IO. Pathophysiological changes that affect drug disposition in protein-energy malnourished children. Nutr Metab 2009;50:6
63. Fillol F, Sarr J, Boulanger D, et al. Impact of child malnutrition on the specific anti-plasmodium falciparum antibody response. Malar J 2009;8:116
64. Deen JL, Walraven GEL, von Seidlein L. Increased risk for malaria in chronically malnourished children under 5 years of age in Rural Gambia. J Trop Pediatr 2002;48:78-83 (Pubitemid 34461029)
65. Danquah I, Dietz E, Zanger P, et al. Reduced efficacy of intermittent preventive treatment of malaria in malnourished children. Antimicrob Agents Chemother 2009;53:1753-9
66. Kokwaro G, Mwai L, Nzila A. Artemether/lumefantrine in the treatment of uncomplicated falciparum malaria. Expert Opin Pharmacother 2007;8:75-94 (Pubitemid 46070831)
67. Murphy JL, Badaloo AV, Chambers B, et al. Maldigestion and malabsorption of dietary lipid during severe childhood malnutrition. Arch Dis Child 2002;87:522-5 (Pubitemid 35440705)
68. Oshikoya KA, Sammons HM, Choonara I. A systematic review of pharmacokinetics studies in children with protein-energy malnutrition. Eur J Clin Pharmacol 2010;66:1025-35
69. Cho MK, Kim YG, Lee MG, et al. Suppression of Rat Hepatic Cytochrome P450s by protein-calorie malnutrition: complete or partial restoration by cysteine or methionine supplementation. Arch Biochem Biophys 1999;372:150-8
70. Aw TY, Jones DP. Control of glucuronidation during hypoxia -limitation by udp-glucose pyrophosphorylase. Biochem J 1984;219:707-12 (Pubitemid 14141731)
71. Hamberg O, Ovesen L, Dorfeldt A, et al. The effect of dietary energy and protein-deficiency on drug-metabolism. Eur J Clin Pharmacol 1990;38:567-70 (Pubitemid 20206029)
72. Stein AJ. Global impacts of human mineral malnutrition. Plant Soil 2009;335:133-54
73. Macdougall LG, Moodley G, Eyberg C, et al. Mechanisms of anemia in protein-energy malnutrition in Johannesburg. Am J Clin Nutr 1982;35:229-35 (Pubitemid 12121020)
74. Oshikoya K, Sammons H, Choonara I. A systematic review of pharmacokinetics studies in children with protein-energy malnutrition. Eur J Clin Pharmacol 2010;66:1025-35
75. Jefford CW. New developments in synthetic peroxidic drugs as artemisinin mimics. Drug Discov Today 2007;12:487-95 (Pubitemid 46783690)
76. Vennerstrom JL, Arbe-Barnes S, Brun R, et al. Identification of an antimalarial synthetic trioxolane drug development candidate. Nature 2004;430:900-4 (Pubitemid 39119218)